Pharma major Novartis received a setback from the Indian Patent Office after the patent on its blockbuster cardiac drug Vymada was revoked due to lack of novelty, the Times of India reported on ...
The Controller General of Patents, Designs and Trademarks (CGPDTM), the Indian Patent Office, has annulled the patent granted to Novartis for its cardiac drug Vymada, also sold internationally as ...
Dr Ajay Kaul, chairman, cardiac sciences with Fortis hospital in Noida, pointed out that nearly 1.5 million new patients are admitted with chronic heart failure every year adding to the already ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results